LOADING
Comparing Johnson & Johnson (JNJ) and Merck & Company (MRK), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $618.6B | $305.1B |
| P/E Ratio | 29.8 | 34.8 |
| Forward P/E | 22.2 | 24.4 |
| PEG Ratio | 4.94 | 6.10 |
| EPS | $8.63 | $3.55 |
| Revenue Growth (YoY) | 9.9% | 4.9% |
| Profit Margin | 21.8% | 13.6% |
| Return on Equity | 26.4% | 18.9% |
| Dividend Yield | 2.01% | 2.62% |
| Beta | 0.23 | 0.20 |
| 52-Week High | $269.43 | $130.29 |
| 52-Week Low | $155.89 | $74.18 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.